Prescribe Right
Prescribe Right
  • Home
  • About
    • Endorsements
    • Published Articles
    • Consulting
    • Effective Pharmacotherapy
  • Pipeline News
    • Podcast
    • Recent Tweets
  • Pharmaceutical Pipeline Tracker
    • Access Pharmaceutical Pipeline Tracker
    • Pharmaceutical Pipeline Tracker Demo
    • Sample Drug Review
    • Case Studies >
      • Monitoring Drugs With PDUFA Dates
      • Monitoring Drugs By Therapeutic Category
      • Monitoring by Indication
      • Research a Single Drug
    • Sample Searches >
      • Single Drug Report Sample
      • Indication Search Sample
      • Drug Class Search Sample
      • Therapeutic Area Search Sample
      • Company Search Sample
  • Contact Us
  • Home
  • About
    • Endorsements
    • Published Articles
    • Consulting
    • Effective Pharmacotherapy
  • Pipeline News
    • Podcast
    • Recent Tweets
  • Pharmaceutical Pipeline Tracker
    • Access Pharmaceutical Pipeline Tracker
    • Pharmaceutical Pipeline Tracker Demo
    • Sample Drug Review
    • Case Studies >
      • Monitoring Drugs With PDUFA Dates
      • Monitoring Drugs By Therapeutic Category
      • Monitoring by Indication
      • Research a Single Drug
    • Sample Searches >
      • Single Drug Report Sample
      • Indication Search Sample
      • Drug Class Search Sample
      • Therapeutic Area Search Sample
      • Company Search Sample
  • Contact Us
Pipeline News and Updates
Picture

Update for the Week Ending February 1, 2020

2/3/2020

 
Regulatory Update
  • The FDA approved the oral peanut-protein immunotherapy, AR101 (Palforzia, Aimmune Therapeutics) on 1/31/2020 for the reduction of allergic reaction incidence and severity in patients aged 4-17 years old with a peanut allergy.
    • Palforzia was approved with a REMS program requiring special training for prescribers and the initial dosing and each dose escalation to be done in a healthcare setting. It is also required that parents or caregivers be counseled on the need to have injectable epinephrine available. 
    • Aimmune set WAC for Palforzia at $890 per month or $10,680 per year. ICER released a review of AR101 and DBV Technologies (DBVT)’s Viaskin Peanut in July 2019. ICER expressed concern regarding the lack of long-term data for safety and effectiveness, desensitization did not eliminate the need to be cautious with peanut exposure, and increase in allergic reaction requiring epinephrine was seen during clinical trials. 
    • The panel also did not find evidence to support AR101 and Viaskin Peanut to have a benefit over avoidance of peanuts or non-commercialized oral immunotherapy. 
    • In a pharmacoeconomic analysis, ICER estimated a benchmark fair-market price of $4,800-7,200 per year for Palforzia and $3,000-$4,500 per year for Viaskin Peanut, which has a PDUFA Date of August 5, 2020.
  • The FDA granted a priority review for Lilly, Loxo Oncology’s selpercatinib for the treatment of advanced RET fusion-positive non-small cell lung cancer, RET-mutant medullary thyroid cancer and RET fusion-positive thyroid cancer and set a PDUFA date in 3Q20.
  • The FDA accepted the NDA for Alkermes’ olanzapine/samidorphan for the treatment of schizophrenia and bipolar I disorder and set a PDUFA date in 4Q20.
  • PharmaMar has an Expanded Access Program for lurbinectedin to treat U.S. patients with relapsed Small Cell Lung Cancer, who are unable to enter clinical trials and have no alternatives.
  • The FDA designated Fulcrum Therapeutics/GlaxoSmithKline’s losmapimod an orphan drug for the treatment of facioscapulohumeral muscular dystrophy.
  • The FDA granted Resverlogix’s apabetalone Breakthrough Therapy status in combination with top standard of care, including high-intensity statins, for the secondary prevention of major adverse cardiac events in patients with type 2 diabetes mellitus and recent acute coronary syndrome.
  • Bayer submitted an NDA for nifurtimox for the treatment of Chagas disease in January 2020.
  • THE EMA accepted the MAA for Gilead Sciences, Kite Pharma’s KTE-X19.
  • The EMA accepted the MAA for Seattle Genetics/Cascadian Therapeutics’ tucatinib, combined with trastuzumab and capecitabine, for the treatment of HER2-positive breast cancer.
  • CHMP recommended approval of Esperion Therapeutics’ bempedoic acid for the treatment of adults with primary hypercholesterolemia.​
Announced Research Updates
 
Sanofi announced that in a 52-week, 36 patient, Phase II/III trial, treatment with olipudase resulted in a relative improvement of 22% in the predicted diffusing capacity of carbon monoxide (DLco) and a 39.5% decrease in spleen size compared to a 3% DLco improvement and a 0.5% decrease in spleen size with placebo in adult patients with acid sphingomyelinase deficiency (Niemann-Pick Disease). However, treatment with olipudase did not improve the Splenomegaly Related Score compared to placebo. Sanofi announced that in a 52-week, 20 patient, open-label, Phase II trial, treatment with olipudase resulted in a relative DLco improvement of 33% and a 49% decrease in spleen size in patients < 18 years old with acid sphingomyelinase deficiency.
 
The NIH announced that it halted a trial after interim data from 5,383 patients enrolled in a 5,407 HIV-negative patient, Phase IIb/III trial, showed that 129/2,694 patients who received the Sanofi Pasteur vaccine with the GSK immunity-boosting adjuvant became infected with HIV compared to 123/2,689 patients that received placebo.
 
Published Research Updates
 
In a 12-week, 111 patient, Phase IIb trial, several dosing regimens of tirzepatide lowered HbA1c more than placebo in patients with type 2 diabetes.
 
In a 13-week, 42 patient, Phase II, open-label trial, treatment with bermekimab resulted in 61% of patients naive to anti-TNF treatment and 63% of patients that failed anti-TNF treatment achieving Hidradenitis Suppurativa Clinical Response (HiSCR), which was defined as a greater than or equal to 50% reduction in inflammatory lesion count and no increase in abscesses or draining fistulas.
 
In an 8-week, 204 patient, Phase II trial, 33.3% of patients treated with serlopitant achieved a 4 point or > worst-itch numeric rating scale (WI-NRS) score compared to  21.1% with placebo in patients with pruritus associated with psoriasis.

Comments are closed.
    Stay informed, subscribe to the 
    ​
    Prescribe Right Pharmaceutical Pipeline Tracker
    Latest Tweets from Prescribe Right

    Archives

    March 2023
    February 2023
    January 2023
    December 2022
    October 2022
    September 2022
    August 2022
    July 2022
    June 2022
    May 2022
    April 2022
    March 2022
    February 2022
    January 2022
    December 2021
    November 2021
    October 2021
    September 2021
    August 2021
    July 2021
    June 2021
    May 2021
    April 2021
    March 2021
    February 2021
    January 2021
    December 2020
    November 2020
    October 2020
    September 2020
    August 2020
    July 2020
    June 2020
    May 2020
    April 2020
    March 2020
    February 2020
    January 2020
    December 2019
    November 2019
    October 2019
    September 2019
    August 2019
    July 2019
    June 2019
    May 2019
    April 2019
    March 2019
    February 2019
    January 2019
    December 2018
    November 2018
    October 2018
    September 2018
    August 2018
    June 2018
    May 2018
    April 2018
    March 2018
    February 2018
    January 2018
    December 2017
    November 2017
    October 2017
    September 2017
    August 2017
    August 2015

    RSS Feed

Services

Pharmaceutical Pipeline Tracker​
Consulting

Company

About
Blog
Tweets

Support

Contact
© COPYRIGHT 2015. ALL RIGHTS RESERVED.